(Q28376481)

1

0 references

P S Ahmed

2

0 references

P Chambers

3

0 references

A S Tyms

4

0 references

J Bedard

5

0 references

J Duchaine

6

0 references

G Falardeau

7

0 references

J F Lavallée

8

0 references

W Brown

9

0 references

R F Rando

10

0 references

T Bowlin

Antiviral Chemistry & Chemotherapy

11

0 references

language of work or name

English

0 references

publication date

March 1999

0 references

published in

0 references

volume

10

0 references

issue

2

0 references

page(s)

79-86

0 references

cites work

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029901000204